Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franziska Michor

Showing results (81-90 of 209) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Investigation|January 27, 2010
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotypeSo Yeon Park, Mithat Gönen, Hee Jung Kim, et al.
Journal for Immunotherapy of Cancer|June 19, 2025
Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>Christopher Graser, Thomas O McDonald, Paul J Catalano, et al.
Nature Structural & Molecular Biology|October 3, 2017
Nuclear topology modulates the mutational landscapes of cancer genomesKyle S Smith, Lin L Liu, Shridar Ganesan, et al.
Journal of Theoretical Biology|November 8, 2003
Somatic selection for and against cancerFranziska Michor, Steven A Frank, Robert M May, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
Functional consequences of a p53-MDM2-p21 incoherent feedforward loopJamie A Dean, Jose Reyes, Michael Tsabar, et al.
Haematologica|March 16, 2012
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trialsMin Tang, Jasmine Foo, Mithat Gönen, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumabChristopher J Graser, Thomas O McDonald, Paul J Catalano, et al.
Plos Computational Biology|May 14, 2010
A differentiation-based phylogeny of cancer subtypesMarkus Riester, Camille Stephan-Otto Attolini, Robert J Downey, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
BESTDR: Bayesian quantification of mechanism-specific drug response in cell cultureThomas O McDonald, Simone Bruno, James P Roney, et al.
Plos One|December 6, 2011
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemiaKevin Leder, Jasmine Foo, Brian Skaggs, et al.
Pageof 21

Showing results (81-90 of 209) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Investigation|January 27, 2010
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotypeSo Yeon Park, Mithat Gönen, Hee Jung Kim, et al.
Journal for Immunotherapy of Cancer|June 19, 2025
Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>Christopher Graser, Thomas O McDonald, Paul J Catalano, et al.
Nature Structural & Molecular Biology|October 3, 2017
Nuclear topology modulates the mutational landscapes of cancer genomesKyle S Smith, Lin L Liu, Shridar Ganesan, et al.
Journal of Theoretical Biology|November 8, 2003
Somatic selection for and against cancerFranziska Michor, Steven A Frank, Robert M May, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
Functional consequences of a p53-MDM2-p21 incoherent feedforward loopJamie A Dean, Jose Reyes, Michael Tsabar, et al.
Haematologica|March 16, 2012
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trialsMin Tang, Jasmine Foo, Mithat Gönen, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumabChristopher J Graser, Thomas O McDonald, Paul J Catalano, et al.
Plos Computational Biology|May 14, 2010
A differentiation-based phylogeny of cancer subtypesMarkus Riester, Camille Stephan-Otto Attolini, Robert J Downey, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
BESTDR: Bayesian quantification of mechanism-specific drug response in cell cultureThomas O McDonald, Simone Bruno, James P Roney, et al.
Plos One|December 6, 2011
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemiaKevin Leder, Jasmine Foo, Brian Skaggs, et al.
Pageof 21